Airain ltd boosted its position in Exelixis, Inc. (NASDAQ:EXEL) by 198.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 323,857 shares of the biotechnology company’s stock after buying an additional 215,232 shares during the period. Airain ltd owned about 0.11% of Exelixis worth $7,018,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Fortaleza Asset Management Inc. purchased a new position in Exelixis during the first quarter worth approximately $106,000. Klingenstein Fields & Co. LLC purchased a new position in Exelixis during the first quarter worth approximately $217,000. Pittenger & Anderson Inc. purchased a new position in Exelixis during the fourth quarter worth approximately $149,000. Commerzbank Aktiengesellschaft FI purchased a new position in Exelixis during the fourth quarter worth approximately $169,000. Finally, National Planning Corp purchased a new position in Exelixis during the fourth quarter worth approximately $255,000. 78.40% of the stock is owned by hedge funds and other institutional investors.
Shares of Exelixis, Inc. (NASDAQ:EXEL) traded down 6.42% during midday trading on Friday, reaching $19.68. 5,867,718 shares of the company were exchanged. The firm has a market capitalization of $5.76 billion, a P/E ratio of 937.14 and a beta of 1.78. Exelixis, Inc. has a 52 week low of $5.70 and a 52 week high of $24.85. The firm has a 50-day moving average of $21.41 and a 200 day moving average of $19.19.
Exelixis (NASDAQ:EXEL) last announced its earnings results on Monday, May 1st. The biotechnology company reported $0.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.06. The company had revenue of $80.90 million for the quarter, compared to analysts’ expectations of $65.23 million. The company’s quarterly revenue was up 425.3% compared to the same quarter last year. During the same period last year, the business earned ($0.27) EPS. On average, equities research analysts expect that Exelixis, Inc. will post $0.18 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Exelixis, Inc. (EXEL) Stake Boosted by Airain ltd” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://transcriptdaily.com/2017/05/20/exelixis-inc-exel-stake-boosted-by-airain-ltd.html.
A number of equities research analysts recently weighed in on the stock. Oppenheimer Holdings Inc. reiterated a “market perform” rating on shares of Exelixis in a report on Thursday, May 4th. Zacks Investment Research lowered shares of Exelixis from a “buy” rating to a “hold” rating in a report on Wednesday, March 1st. Cann reiterated a “hold” rating on shares of Exelixis in a report on Wednesday, April 19th. TheStreet upgraded shares of Exelixis from a “d” rating to a “c+” rating in a report on Tuesday, May 2nd. Finally, Stifel Nicolaus lowered shares of Exelixis from a “buy” rating to a “hold” rating and set a $22.00 price objective for the company. in a report on Tuesday, February 28th. They noted that the move was a valuation call. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $18.37.
In other news, CEO Michael Morrissey sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 9th. The shares were sold at an average price of $21.69, for a total value of $2,169,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jeffrey Hessekiel sold 23,787 shares of the firm’s stock in a transaction that occurred on Wednesday, March 22nd. The shares were sold at an average price of $20.54, for a total transaction of $488,584.98. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,097,718 shares of company stock valued at $24,364,853. 5.90% of the stock is currently owned by insiders.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.